|1.||Liu, Zhao-Qian: 5 articles (09/2012 - 12/2010)|
|2.||Dai, Xing-Ping: 4 articles (09/2012 - 12/2010)|
|3.||Huang, Qiong: 4 articles (09/2012 - 06/2010)|
|4.||Zhou, Hong-Hao: 4 articles (09/2012 - 12/2010)|
|5.||Wang, Tao: 3 articles (01/2015 - 02/2014)|
|6.||Dong, Min: 3 articles (09/2012 - 06/2010)|
|7.||Gong, Zhi-Cheng: 3 articles (09/2012 - 12/2010)|
|8.||Yin, Ji-Ye: 3 articles (09/2012 - 12/2010)|
|9.||Pei, Qi: 3 articles (09/2012 - 06/2010)|
|10.||Wu, Jing: 3 articles (01/2012 - 12/2010)|
|1.||Type 2 Diabetes Mellitus (MODY)
02/01/2014 - "To investigate the associations of NOS1AP rs12742393 polymorphism with the risk of type 2 diabetes mellitus (T2DM) and repaglinide therapeutic efficacy in Chinese patients with T2DM. "
09/01/2012 - "We aimed to determine whether NeuroD1/BETA2 and PAX4 polymorphisms were associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetes mellitus (T2DM) patients. "
01/01/2012 - "The aim of the present study was to evaluate the impact of the UCP2-866 G/A polymorphism on the efficacy of repaglinide in treating patients with diabetes mellitus type 2 (T2DM). "
01/01/2001 - "In clinical trials of up to 1-year's duration, repaglinide maintained or improved glycaemic control in patients with type 2 diabetes mellitus. "
05/01/2012 - "The present study evaluated the effects of KCNQ1 rs2237892 and rs2237895 polymorphisms on repaglinide efficacy in Chinese patients with type 2 diabetes mellitus (T2DM). "
|2.||Hypoglycemia (Reactive Hypoglycemia)
02/01/2005 - "To assess the efficacy of repaglinide and its proclivity for hypoglycemia in a post-marketing study. "
02/12/2014 - "Hypoglycemia was reported in 11.7, 0 and 13.3% of patients in the repaglinide group, placebo group and long-term study, respectively. "
04/01/2010 - "A 76-year-old diabetic patient with impaired renal function and no history of hypoglycemia was receiving treatment with repaglinide 1 mg 3 times daily. "
05/01/2004 - "If the patient wants Ramadan fasting, these patients using Repaglinide can reduce the frequency of hypoglycemia."
11/01/2002 - "Repaglinide-induced hypoglycemia was suspected when a tablet of repaglinide was noted in the drug package that she had been given. "
01/01/2015 - "Therefore, the current study was designed to investigate the associations of PPARD rs2016520 polymorphism with type 2 diabetes mellitus (T2DM) susceptibility and repaglinide therapeutic efficacy in Chinese Han T2DM patients. "
01/01/2015 - "PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus."
04/01/2006 - "Repaglinide in the management of new-onset diabetes mellitus after renal transplantation."
12/01/2014 - "Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus."
02/12/2014 - "In the 16-week multicenter, placebo-controlled, randomized, double-blind, parallel-group trial (the phase III study), patients with type 2 diabetes mellitus with metformin monotherapy were randomly assigned to the repaglinide or placebo group. "
12/01/2000 - "Furthermore, when used in this way, repaglinide has not been associated with weight gain. "
01/01/1999 - "Repaglinide appears to be weight-neutral, but other medications for patients with diabetes can be associated with weight gain. "
06/01/2004 - "Mean weight gain at the end of the study was 1.8 kg in the repaglinide group as compared with 0.7 kg for the nateglinide group. "
01/01/2009 - "Furthermore, acarbose seems to have advantages over repaglinide concerning weight gain and severe hypoglycemic attacks."
01/01/2007 - "Repaglinide is associated with less weight gain than sulphonylureas and the glitazones. "
|5.||Cystic Fibrosis (Mucoviscidosis)
01/01/2014 - " primary objective of this trial is to compare the glycaemic control of oral therapy with Repaglinide with insulin injections in patients with cystic fibrosis related diabetes after 2 years of treatment.The"
01/01/2014 - "Based on an initiative of the German Mukoviszidosis-Foundation, the present study tries to answer the question, whether oral therapy with repaglinide is as effective as insulin therapy in cystic fibrosis patients with early diagnosed diabetes mellitus. "
10/01/2009 - "A three-arm multicenter randomized trial compared 1 year of therapy with premeal insulin aspart, repaglinide, or oral placebo in subjects with cystic fibrosis who had abnormal glucose tolerance. "
10/01/2001 - "Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes."
10/01/2001 - "Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia. "
|5.||Blood Glucose (Blood Sugar)
|9.||glargine (insulin glargine)